title: The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
abstract: Beta-lactam antibiotics, such as piperacillin-tazobactam, are commonly administered frequently throughout the day as intermittent infusions over a period of 30-60 min. However, increasing knowledge of how these antibiotics kill bacteria has made continuous infusion a valuable option to achieve maximal clinical outcomes while consuming the least amount of institutional resources. Continuous infusion of piperacillin-tazobactam is currently used at our hospital because of its clinical and economic benefits when compared with intermittent infusion. This article will review our experience with the administration of piperacillin-tazobactam by continuous infusion and the numerous advantages we have documented. Additionally, advantages related to a reduction in nursing resource consumption will be a focus of discussion.
authors.affiliation: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. skotapati@harthosp.org
authors.forename: Srividya
authors.initials: S
authors.lastname: Kotapati
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Kuti
authors.forename: Erika C
authors.initials: EC
authors.lastname: Geissler
authors.forename: Charles H
authors.initials: CH
authors.lastname: Nightingale
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics / Q000494:pharmacology; D015400:Clinical Nursing Research; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data; D016903:Drug Monitoring; D017850:Economics, Pharmaceutical; D017721:Hospital Costs / Q000706:statistics & numerical data; D006801:Humans; D007262:Infusions, Intravenous / Q000191:economics / Q000295:instrumentation / Q000379:methods* / Q000451:nursing; D015401:Nursing Administration Research; D009741:Nursing Staff, Hospital / Q000191:economics; D018579:Patient Selection; D010397:Penicillanic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000191:economics / Q000494:pharmacology; D010878:Piperacillin / Q000008:administration & dosage* / Q000191:economics / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D013996:Time and Motion Studies; D016896:Treatment Outcome; D016526:Workload
chemical_list: D000900:Anti-Bacterial Agents; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin